RPT1G

DRUG2 trials

Sponsors

Remedy Plan, Inc.

Conditions

Acute Myeloid LeukemiaHealthyMyelodysplastic Syndrome

Phase 1

A Study of RPT1G After Single and Multiple Doses in Healthy Adult Participants

CompletedNCT06667765

Remedy Plan, Inc.Healthy

Start: 2024-11-18End: 2025-05-14Updated: 2025-09-02

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

RecruitingNCT07107126

Remedy Plan, Inc.Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2026-02-13End: 2028-12-01Target: 24Updated: 2026-03-25

Related Papers

Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes/neoplasms.

Journal of Clinical Oncology2026-05-28

Abstract CT267: Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes/neoplasms

Cancer Research2026-04-17

Abstract 3050: RPT1G, a novel hyperbolic NAMPT inhibitor, effectively synergizes with PARP inhibitors in solid tumors <i>in vitro</i> and in a xenograft breast cancer model

Cancer Research2026-04-03

Abstract 442: Crippling cancer’s energy and escape: NAMPT and BCL2 as dual targets in T-ALL.

Cancer Research2026-04-03

First-in-human randomized placebo-controlled Phase 1 study of RPT1G, a novel hyperbolic NAMPT inhibitor for use in acute leukemias: Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers

Blood2025-11-03

Phase 1, open-label, multi-center trial of RPT1G in patients with Relapsed/Refractory Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes/neoplasms

Blood2025-11-03

RPT1G, a novel hyperbolic NAMPT inhibitor, is highly effective against B-cell non-Hodgkin's lymphoma with germinal center origin

Blood2025-11-03